Nasopharyngeal carcinoma

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented at ESMO 2025

6 days ago talkbio0Tagged Antibody-Drug Conjugates, BL-B01D1 - 303, Epidermal Growth Factor Receptor, iza-bren, Nasopharyngeal carcinoma, ORR, Phase 3 Clinical Trials, SystImmune

SystImmune; iza-bren; BL-B01D1-303; Phase III trial; nasopharyngeal carcinoma; dual primary endpoints; ORR; antibody-drug conjugate (ADC); EGFR×HER3 bispecific; ESMO 2025

Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer

6 months ago talkbio0Tagged Akeso, Akeso 's, Anniko, Approved, Inhibitor, Nasopharyngeal carcinoma, PDCD1 gene, United States Food and Drug Administration

United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

9 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts